List of Authors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
List of Authors
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
K. Vigneshwar Reddy
S.N. Kabekkodu
Shivajirao S. Kadam
Balaji V. Kadri
J.A. Kaduk
Andreas Kaerner
Mansoor A. Kahn
Kenneth I. Kaitin
Madhu Kallam
Greg Kalten
Madhav Kamat
Vivek Kamat
Phil Kaminsky
Anil Kane
R. Kapil
D. Kapoor
Cheryl Karas
Matthias Karl
Shreekant Karmarkar
Nina Karpynec
L. Lee Karras, CEO of AAIPharma Services
KR Karu
Kashyap R. Wadekar
Ron Kasner
O.P. Katare
Abishek Kathuria
Paula R. Katz
Jon S. Kauffman, PhD
Harpinder Kaur
Deepak Kaushik
Pauly Kavalakatt
Gordon Kearney
Colin Keary
Rodney Keck
Roger Keintz
Susanne Keitel
Kathleen Kelly
Paul Kelly
Stephen Kemp
Cirrus, a KEMWELL company
John S. Kent
Josh Kerst
Stefan Kettelhoit
Charles N. Kettler
Tim Keutzer
Said Khalil
Mansoor A. Khan, RPh, PhD
Shamsuddin Sultan Khan
Naushad Khan Ghilzai
Naushad M. Khan Ghilzai
Mahdu Khanna
Vivek Kharb
Johannes G. Khinast
San Kiang
Maura Kibbey
Robert G. Kieffer, PhD
Chris Kilbee
Kevin Killeen
Mark Kimball
Eric Kinaitis
Harry King
Simon King
Carol A. Kingsmill
Christopher Kinzie
Jeffrey P. Kiplinger
Paul Kippax
Doug Kirsch
Rakesh Kishan
M. Serpil Kislalioglu, PhD
Janice Kite
Sean L Kitson
Tom Klaff, CEO
Friedbert Klefenz
George F. Klein
Michael T. Klein
Brent Kleintop
Silke Klick, PhD
David Klug
Stephen Knight
Alyssa Knightly
Brian D. Koblinski
Juergen Koch
William F. Koch
Norbert Kockmann
Voula Kodoyianni, PhD
Martin Koeberle
Peter Koklitis
Mamoru Kokubo
Kevin J. Kolodsick
K. Kolter, PhD
Karl Kolter
Bekki Komas
Darek Kominek
Hans Konig-Bastiaan
Antoinette Konski
Vadim Konyushkevich
Matthew Kopecky
Vishal Koradia
George Koroneos
Laila Kott
Back to Top

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here